Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Establishment of anti-C1q monoclonal antibodies to measure serum C1q levels discriminating disease severity subsets of rheumatoid arthritis within 5 years of onset.

Yukioka C, Ebina K, Shimaoka Y, Yukioka M, Yoshikawa H, Nakata K, Ochi T.

Mod Rheumatol. 2019 Sep 19:1-5. doi: 10.1080/14397595.2019.1657653. [Epub ahead of print]

PMID:
31422723
2.

Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs.

Mamehara A, Sugimoto T, Sugiyama D, Morinobu S, Tsuji G, Kawano S, Morinobu A, Kumagai S.

Kobe J Med Sci. 2010 Sep 30;56(3):E98-107.

3.

Periodontal Disease as a Risk Factor for Rheumatoid Arthritis: A Systematic Review.

Kaur S, White S, Bartold M.

JBI Libr Syst Rev. 2012;10(42 Suppl):1-12.

PMID:
27820156
4.

Baseline serum level of matrix metalloproteinase-3 as a biomarker of progressive joint damage in rheumatoid arthritis patients.

Galil SM, El-Shafey AM, Hagrass HA, Fawzy F, Sammak AE.

Int J Rheum Dis. 2016 Apr;19(4):377-84. doi: 10.1111/1756-185X.12434. Epub 2014 Oct 7.

PMID:
25292349
5.

Leucine-rich α2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis.

Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, Hattori K, Kohsaka H, Miyasaka N, Takeuchi T, Naka T.

Arthritis Rheumatol. 2015 May;67(8):2056-60. doi: 10.1002/art.39164.

6.

Serum C1q levels as a prognostic guide to articular erosions in patients with rheumatoid arthritis.

Ochi T, Yonemasu K, Iwase R, Sasaki T, Tsuyama K, Ono K.

Arthritis Rheum. 1984 Aug;27(8):883-7.

PMID:
6331829
7.

Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction.

Ebina K, Fukuhara A, Ando W, Hirao M, Koga T, Oshima K, Matsuda M, Maeda K, Nakamura T, Ochi T, Shimomura I, Yoshikawa H, Hashimoto J.

Clin Rheumatol. 2009 Apr;28(4):445-51. doi: 10.1007/s10067-008-1074-y. Epub 2008 Dec 16.

PMID:
19085030
8.

Matrix metalloproteinase-3 levels in relation to disease activity and radiological progression in rheumatoid arthritis.

Tuncer T, Kaya A, Gulkesen A, Kal GA, Kaman D, Akgol G.

Adv Clin Exp Med. 2019 May;28(5):665-670. doi: 10.17219/acem/94065.

9.

Unique correlation between mutated citrullinated vimentine IgG autoantibodies and markers of systemic inflammation in rheumatoid arthritis patients.

Zahran WE, Mahmoud MI, Shalaby KA, Abbas MH.

Indian J Clin Biochem. 2013 Jul;28(3):272-6. doi: 10.1007/s12291-012-0272-1. Epub 2012 Oct 17.

10.

Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study.

Innala L, Berglin E, Möller B, Ljung L, Smedby T, Södergren A, Magnusson S, Rantapää-Dahlqvist S, Wållberg-Jonsson S.

Arthritis Res Ther. 2014 Apr 14;16(2):R94. doi: 10.1186/ar4540.

11.

Rheumatoid arthritis patients have elevated antibodies to cross-reactive and non cross-reactive antigens from Proteus microbes.

Rashid T, Jayakumar KS, Binder A, Ellis S, Cunningham P, Ebringer A.

Clin Exp Rheumatol. 2007 Mar-Apr;25(2):259-67.

PMID:
17543151
12.

Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis.

Jorgensen C, Picot MC, Bologna C, Sany J.

Ann Rheum Dis. 1996 Feb;55(2):94-8.

13.

The clinical features of rheumatoid arthritis.

Grassi W, De Angelis R, Lamanna G, Cervini C.

Eur J Radiol. 1998 May;27 Suppl 1:S18-24. Review.

PMID:
9652497
14.

The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.

Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, Miyasaka N, Koike T.

Ann Rheum Dis. 2016 Jan;75(1):75-83. doi: 10.1136/annrheumdis-2015-207511. Epub 2015 Jul 2.

15.

Clinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapy.

Niki Y, Takeuchi T, Nakayama M, Nagasawa H, Kurasawa T, Yamada H, Toyama Y, Miyamoto T.

PLoS One. 2012;7(5):e37447. doi: 10.1371/journal.pone.0037447. Epub 2012 May 21.

16.

Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate.

Patro PS, Singh A, Misra R, Aggarwal A.

J Rheumatol. 2016 Apr;43(4):731-7. doi: 10.3899/jrheum.150998. Epub 2016 Feb 1.

PMID:
26834220
17.

Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity.

Schwedler C, Häupl T, Kalus U, Blanchard V, Burmester GR, Poddubnyy D, Hoppe B.

Arthritis Res Ther. 2018 Mar 14;20(1):44. doi: 10.1186/s13075-018-1540-0.

18.
19.

[Significance of different T follicular helper subsets in rheumatoid arthritis].

Chen XM, Li J, Zhang XY, Jin YB, Yu D, Sun XL, Wu LJ, He J, Li ZG.

Beijing Da Xue Xue Bao Yi Xue Ban. 2016 Dec 18;48(6):958-963. Chinese.

20.

Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis.

Murota A, Suzuki K, Kassai Y, Miyazaki T, Morita R, Kondo Y, Takeshita M, Niki Y, Yoshimura A, Takeuchi T.

Cytokine. 2016 Feb;78:87-93. doi: 10.1016/j.cyto.2015.12.002. Epub 2015 Dec 14.

PMID:
26700586

Supplemental Content

Support Center